Sortina Pharma, an oncology focused startup founded in 2020 based on research originating from Gothenburg University, today announces the official publication of the issued Swedish patent no. 2151469-0, which relates to novel sortilin binding molecules inhibiting the binding of effector molecules to sortilin.